Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection

NCT06982534 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06982534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06982534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2025
Completion date
January 31, 2040
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis (ssc)